Understanding the complexity ofthe polygenic disease, cancer, has remained and continues to remain one of the greatest challenges to mankind's health. Technological milestones in genomics have initiated a new approach in the development of novel anticancer drugs to specific genes selectively targeting cancer cells while sparing normal cells (1). Although this approach is promising, the heterogeneity of the disease involving multigene complexity calls upon a complementary approach to effectively develop novel anticancer drugs either to specific tumors or with broad range of antitumor activity.

0 0

Post a comment